Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has reported that alli - the first clinically proven over the counter weight loss aid - is available in pharmacies across Europe.
Subscribe to our email newsletter
GlaxoSmithKline (GSK) has received a non-prescription license for alli (orlistat 60mg); the first time the European Commission has approved a non-prescription product for weight loss.
The centrally approved marketing authorization means GSK can introduce alli for adults with a body mass index of 28kg per metre square or more, in all 27 EU member countries.
Manfred Scheske, president of consumer healthcare Europe at GSK, said: “alli offers adults a real opportunity for losing weight. alli has been well received by millions of people in the US and we are very excited about the number of people it could help across Europe achieve their goal to lose weight.”